Annexon (ANNX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.25

Estimate

-$0.28

Surprise

+10.6%

Score today

4.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Annexon (ANNX) reported a narrower loss than forecast — adjusted EPS of -$0.25 against the -$0.28 estimate (a 10.6% beat on a still-unprofitable quarter).

• Annexon Reports Third Quarter 2026 Financial Results and Business Updates — fiscal.ai, 2026-11-09
• Annexon Q3 EPS $(0.25) Beats $(0.28) Estimate — benzinga, 2026-11-09

TrendMatrix currently rates ANNX Sell at 4.7/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +10.6% surprise compares with a +7.7% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$4.13

Price target

$4.43

Stop

$3.85

Upside to target

+7.1%

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$801.9M

P/E (fwd)

-3.9

52-week range

$2.54–$7.18

Off 52-week high

42.4%

RSI (14)

58

Volume vs avg

0.20×

Score today

4.7/10